DGAP-News: Biotest AG: Kreissparkasse Biberach continues to

DGAP-News: Biotest AG / Key word(s): Statement Biotest AG: Kreissparkasse Biberach continues to be major shareholder of Biotest 14.01.2016 / 14:11 The issuer is solely responsible for the content of this announcement. --------------------------------------------------------------------------- PRESS RELEASE Kreissparkasse Biberach continues to be major shareholder of Biotest Dreieich, 14. January 2016. "Biotest has today published a notification of existing voting rights, pursuant to section 41, para. 4f of the German Securities Trading Act (WpHG) of the District of Biberach which submitted this notification controlling the Kreissparkasse Biberach ("KSK"). Even if this notification of existing voting rights shows a voting share in Biotest AG of zero, the KSK is economically speaking still anchor shareholder of Biotest AG and has retained its Biotest shareholding and not reduced it to zero. The background to this technical notification of existing voting shares is an amendment to the German Securities Trading Act which recently came into force as a result of the implementation of the Transparency Directive/ Amending Directive (Transparenzrichtlinie-Änderungsrichtlinie) on the European harmonization of participation transparency which we would like to explain as follows: The KSK holds its shareholding in Biotest AG via so-called legally independent open special funds ("Special Alternative Investment Funds" or "Special AIFs"). As a result of the aforementioned amendment to the German Securities Trading Act, which became effective at the end of November 2015, investors in such a Special AIF (in this case the KSK) no longer fall under the voting rights notification obligation according to sections 21 et sqq. of the German Securities Trading Act which was the case, until today. In this respect, the KSK, as investor in such a "Special AIF", and the District of Biberach controlling the KSK, which have both to date been subject to notification obligations according to sections 21 et sqq. of the German Securities Trading Act, are obliged to submit a notification of existing voting shares according to section 41, para. 4f of the German Securities Trading Act by 15 January 2016 and to state a voting share reduced to zero, although the KSK is economically speaking holder of the respective Biotest ordinary shares. The District of Biberach has met this obligation with today's published notification of existing voting shares." Disclaimer This document contains forward-looking statements on overall economic development as well as on the business, earnings, financial and assets position of Biotest AG and its subsidiaries. These statements are based on current plans, estimates, forecasts and expectations of the company and are thus subject to risks and elements of uncertainty that could result in significant deviation of actual developments from expected developments. The forward-looking statements are only valid at the time of publication. Biotest does not intend to update the forward-looking statements and assumes no obligation to do so. About Biotest Biotest is a provider of plasma proteins and biological drugs. With a value added chain that extends from pre-clinical and clinical development to worldwide sales, Biotest has specialised primarily in the areas of clinical immunology, haematology and intensive medicine. Biotest develops and markets immunoglobulins, coagulation factors and albumins based on human blood plasma. These are used for diseases of the immune and haematopoietic systems. In addition Biotest develops monoclonal antibodies in the indications of cancer of plasma cells and systemic lupus erythematosus which are produced by recombinant technologies. Biotest has more than 2,200 employees worldwide. The preference shares of Biotest AG are listed in the SDAX on the Frankfurt stock exchange. Biotest AG, Landsteinerstr. 5, 63303 Dreieich, www.biotest.de Dr. Monika Buttkereit tel.: +49 (0) 6103 801-4406, email: investor_relations@biotest.de Securities' ID No., ISIN ordinary shares: 522720, DE0005227201 Securities' ID No., ISIN preference shares: 522723, DE0005227235 Listing: Prime Standard Open Market: Berlin-Bremen, Düsseldorf, Frankfurt, Hamburg, Hannover, München, Stuttgart --------------------------------------------------------------------------- 14.01.2016 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de --------------------------------------------------------------------------- Language: English Company: Biotest AG Landsteinerstraße 5 63303 Dreieich Germany Phone: 0 61 03 - 8 01-0 Fax: 0 61 03 - 8 01-150 E-mail: investor_relations@biotest.de Internet: http://www.biotest.de ISIN: DE0005227235, DE0005227201 WKN: 522723, 522720 Indices: SDAX Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Stuttgart End of News DGAP News Service --------------------------------------------------------------------------- 429409 14.01.2016